Editor's Choice
Gilead Wins HIV Patent Suit, Nabs Oncology, and Inflammation Startup15 May 2023
Gilead Sciences has won a lawsuit in Delaware where a jury ruled that the company’s HIV prevention drugs, Truvada and... Continue Reading
|
Pharma’s Biggest Losses: Once-Dropped Drugs Make Lucrative Comebacks15 May 2023
In March 2023, Sanofi acquired the diabetes drug Tzield and its owner, Provention Bio, for $2.9 billion. The drug had... Continue Reading
|
Lucem Health Secures $7.7M for Agnostic AI-Powered Platform15 May 2023
Lucem Health, a portfolio company of Mayo Clinic Platform, has successfully raised $7.7 million in a Series A venture capital... Continue Reading
|
Bioventus Announces Divestiture of its Wound Business15 May 2023
Bioventus Inc. has signed a definitive agreement to sell its Wound business, which includes TheraSkin and TheraGenesis skin substitutes, to... Continue Reading
|
AmerisourceBergen Launches Pharmacy Telehealth Pilot with SteadyMD09 May 2023
Healthcare company AmerisourceBergen has partnered with telehealth infrastructure provider SteadyMD to offer a telehealth solution for Test to Treat opportunities... Continue Reading
|
Carbon Health, Anthem Blue Cross of California in Public Contract Dispute09 May 2023
Virtual primary and urgent care provider Carbon Health has published a blog post accusing health insurer Elevance Health, which operates... Continue Reading
|
The Importance of Decoding Health Data to Every Organization09 May 2023
Data is everywhere, and the modern age is witnessing an exponential increase in data collection. However, data-driven decision-making is only... Continue Reading
|
45% of U.S. Adults Say AI In Healthcare Is Trustworthy, 20% Note Privacy Of Health Data Violated09 May 2023
A recent healthcare tech survey by Healthcare.com polled over 1,000 US adults and found that 20% of Americans feel their... Continue Reading
|
3M Enters Agreements with Pierrel for the Sale of Assets Associated with the Dental Local Anesthetic Business09 May 2023
3M has agreed to sell certain assets related to its dental local anesthetic portfolio to Pierrel S.p.A. for $70m. The... Continue Reading
|
Enzolytics Inc. Continues Progress with Business Combination; Biogenysis Announces Team and Plans for Success02 May 2023
Enzolytics, a drug development company, has appointed Dr. Gaurav Chandra as the Chief Executive Officer and Chairman of Biogenysis. Enzolytics... Continue Reading
|